Quantcast

Latest Biologic Stories

2014-05-19 16:24:15

NEUDORF SPECIAL ECONOMIC ZONE, ST. PETERSBURG, Russia, May 19, 2014 /PRNewswire/ -- Head of the Russian Government Dmitri Medvedev visited today CJSC BIOCAD's [http://www.biocad.ru/en/we ] commercial manufacturing facility for mAb-based therapeutic proteins. This private facility is unique in Russia and Easter Europe. It produces monoclonal antibodies-based APIs for biological products that are widely used in treating oncological and autoimmune disorders. The visit occurred in...

2014-05-19 08:29:14

PASADENA, Calif., May 19, 2014 /PRNewswire/ -- Meditope Biosciences, Inc., a biotechnology company developing novel antibody-drug conjugates (ADC) using its proprietary monoclonal antibody (mAb) technology platform, today announced the appointment of C. Dan Dumitru, M.D., Ph.D., as Vice President of Translational Research. "We are delighted to expand our highly focused team to include Dan, who brings a strong background in preclinical and translational drug development for biologics...

2014-05-19 08:28:28

REDWOOD CITY, Calif., May 19, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus"), a leading biologics platform company focused on biosimilars, announced today the closing of a Series C Preferred investment round raising $55 million. New investors KKR & Co. L.P. ("KKR"), Venrock, RA Capital Management, Rock Springs Capital and Fidelity Biosciences joined existing investors Sofinnova Ventures, Lilly Ventures and Vivo Capital in the transaction. "We are very pleased to have...

2014-05-15 08:31:49

Biologic with unique therapeutic approach for OA, which affects over 80 million worldwide CLEVELAND, May 15, 2014 /PRNewswire-USNewswire/ -- NovelMed Therapeutics announced today positive data using its novel, humanized monoclonal antibody in two well-established models of osteoarthritis (OA), characterized by osteophyte formation and cartilage loss. Approximately one in ten people worldwide are affected by OA, with the total number of afflicted patients expected to increase from 75...

2014-05-15 08:31:13

-- Conference Call Today, May 15, 2014, at 8:30 a.m. (EDT) -- ROCKVILLE, Md., May 15, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today reported financial results for the three months ended March 31, 2014, and provided an operational progress update. http://photos.prnewswire.com/prnvar/20130522/MM19465LOGO Recent Operational Highlights...

2014-05-14 12:31:58

LONDON, May 14, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:PharmaPoint: Crohn's Disease - Global Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/therapeutic/pharmapoint_crohns_disease_global_drug_forecast_market_analysis_2022.htmlPharmaPoint: Crohn's Disease - Global Drug Forecast and Market Analysis to 2022SummaryThe Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the...

2014-05-14 08:28:16

LONDON, May 14, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:PharmaPoint: Crohn's Disease - 5EU Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/therapeutic/pharmapoint_crohns_disease_5eu_drug_forecast_market_analysis_2022.htmlPharmaPoint: Crohn's Disease - 5EU Drug Forecast and Market Analysis to 2022SummaryThe Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the...

2014-05-12 08:31:48

REDWOOD CITY, Calif., May 12, 2014 /PRNewswire/ -- Coherus Biosciences, Inc. ("Coherus"), is pleased to announce the appointment of Lisa M. Bell, Ph.D. as Senior Vice President, Global Regulatory Affairs. Dr. Bell joins Coherus with more than 15 years of experience in global regulatory affairs and drug development across various therapeutic areas at preeminent biotech companies. "Lisa brings a strong strategic, scientific and global mindset to the regulatory strategy for our...

2014-05-09 08:25:42

-- Conference Call Scheduled for Thursday, May 15, 2014, at 8:30 am EDT -- ROCKVILLE, Md., May 9, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it intends to release its financial results for the three months ended March 31, 2014 on Thursday, May 15, 2014. The Company will hold an investor conference call on...

2014-05-08 08:31:53

ROCKVILLE, Md., May 8, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it has been granted new patents in Europe and has received a notice of allowance in Australia that provide composition of matter coverage for various aspects of its C. difficile (C. diff) program. The Company's extensive C. diff patent estate...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related